Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity

A method of preventing and treating a disease caused by fibrosis of an organ or tissue in vivo in a subject in need thereof, comprising:

• providing a pharmaceutical composition comprising, as an active ingredient, a chromone derivative represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof,
• wherein the disease is selected from the group consisting of idiopathic pulmonary fibrosis, myelofibrosis, and kidney fibrosis,
• in Chemical Formula 1,
• R1 is hydrogen, a methoxy group, a trifluoromethyl group or an acetoxy group,
• R2 is a methyl group, an ethyl group, a cyclopentyl group, a cyclohexyl group, a phenyl group or a benzyl group,
• R3 is hydrogen, an ethyl group, an acetyl group, an acetoxy group, a carboxyl group, a benzoyloxy group or a 3,4,5-trihydroxybenzoyloxy group, and
• R4 to R6 are each independently hydrogen, a hydroxyl group, a methyl group, an acetoxy group, a carboxyl group or a benzoyloxy group;
• and
• administering the pharmaceutical composition to the subject, wherein the disease is prevented and treated.